Atherosclerotic Cardiovascular Disease
Conditions
Interventions
Sponsors
Maruyama Hideki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Fasting LDL-C >= 70 mg/dL at randomization visit 2.Stable (greater than or equal to 4 weeks) and well-tolerated lipid-lowering regimen (including e.g. with or without Ezetimibe) that must include a high-intensity statin therapy with either atorvastatin greater than or equal to 40 mg QD or rosuvastatin greater than or equal to 20 mg QD 3.Established CV disease defined as ANY of the following three conditions -Spontaneous Myocardial infarction >= 4 weeks from screening visit -History of ischemic stroke occurred >= 4 weeks prior to the Screening visit -Symptomatic peripheral arterial disease (PAD) evidenced by either intermittent claudication with ankle brachial index (ABI) < 0.85, prior peripheral arterial revascularization procedure, or, amputation due to atherosclerotic disease.
Exclusion criteria
Exclusion criteria: 1.Acute coronary syndrome, stroke, peripheral arterial revascularization procedure or amputation due to atherosclerotic disease < 4 weeks before screening visit 2.Treatment with PCSK9 inhibitors (e.g. evolocumab, alirocumab) within 90 days or planned use post first study visit 3.Planned or expected cardiac, cerebrovascular or peripheral artery surgery or re-vascularization within the 6 months after the first study visit 4.Heart failure NYHA class III or IV 5.Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver 6.Previous exposure to inclisiran or any other non-mAb PCSK9-targeted therapy, either as an investigational or marketed drug within 2 years 7.Severe concomitant non-CV disease that is expected to reduce life expectancy to less than 5 years 8.History of malignancy that required surgery radiation therapy and/or systemic therapy during the 3 years prior to the first study visit 9.Pregnant or nursing (lactating) women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to First Occurrence of 3P-MACE | — |
Countries
Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, Denmark, Estonia, Finland, France, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mauritius, Mexico, Netherlands, New Zealand, Norway, Philippines, United States
Contacts
Public ContactHideki Maruyama
Novartis Pharma. K.K.
Outcome results
None listed